Explore ONMD stock price, technical analysis, earnings, and forecast. Is ONMD stock a buy? Get balanced insights on OneMedNet’s valuation and outlook as of February 2026.
Introduction
OneMedNet Corporation (ONMD) runs a platform for healthcare data. It gives life sciences firms access to real-world clinical data for research. Investors watch ONMD stock now due to its AI push and subscription growth. Broader market volatility in small-cap tech stocks affects it amid economic shifts.
Latest Stock Price & Trend
ONMD stock closed at $1.22 on February 27, 2026. It ranged from $0.72 to $1.40 that day, up sharply from prior levels. The 52-week low sits at $0.30, while the high is $4.22.
Over five days, ONMD showed volatility with high volume. One-month trends point to gains around 80% amid news. Year-to-date, it rose over 60% from lows. Six-month performance reflects a rebound from $0.30 lows.
The overall trend looks bullish short-term on volume spikes. Investors see momentum, but volatility warns of pullbacks. Watch for sustained volume to confirm uptrend.
Technical Analysis
Support levels hover near $0.72, the recent low. Resistance sits at $1.40 and $4.22 yearly high. Support acts as a price floor where buyers step in. Resistance caps upside until broken.
RSI at 45 signals neutral, not overbought or oversold. Values above 70 mean overbought; below 30 oversold. This shows balanced momentum. MACD leans sell with negative histogram. It spots trend changes via moving average crossovers.
The 50-day moving average is about $0.65, below price. 200-day average near $0.76 trails too. No golden cross (bullish 50 over 200) or death cross yet. Trading volume surged to 203 million shares, far above 250k average. High volume backs moves.
Analyst Ratings & Price Targets
Few analysts cover ONMD. No major Buy/Hold/Sell counts from Wall Street firms like Bloomberg. Some forecasts eye $11.43 average target, high $12.01, low $11.04. This implies big upside but lacks broad consensus.
Neutral sentiment prevails due to limited coverage. Investors use it as a gauge, but small caps like ONMD often lack deep ratings. Recent views highlight growth potential.
Insider Activity
Recent SEC filings show director grants like 45,000 RSUs vesting in 2024. One insider holds 2.5 million shares directly. No big buys or sells noted lately.
Trends show compensation grants, not open-market buys. This implies steady confidence but no aggressive accumulation. Watch for sales as caution signal.
Valuation Analysis
Trailing P/E is -9.16 on losses. Forward P/E unavailable. Price-to-sales high given $494k TTM revenue. EPS TTM at -0.05. Free cash flow negative.
Debt cut 75% to low levels; cash position stable. Revenue growth hit 4.1x bookings in 2025 at $2.79M. Versus peers like small medtech, ONMD looks speculative. It appears overvalued on fundamentals but growth-priced.
Recent Earnings & Catalysts
2025 bookings reached $2.79M, up 4.1x. Q2 2025 net income swung to $2.98M profit from loss. Revenue dipped to $155k. EPS rose to $0.07.
Guidance eyes AI launch with Palantir in 2026. Catalysts include neuro deals worth millions and 37% network growth to 186M exams. Earnings boosted stock on subscription shift.
Bullish Case
Subscription revenue grows fast. AI-Palantir integration speeds data access. Network expanded 37% yearly. Enterprise deals size up. Demand for real-world data rises in pharma.
Bearish Case
Revenue still tiny at $494k TTM. Losses persist long-term. Competition from big data firms. Margin pressure in small caps. Regulatory risks in health data. Economic slowdown hits R&D budgets.
Market Sentiment
Short interest data limited. Options activity low on small cap. Institutional ownership modest. Retail drove recent volume spikes. Sentiment tilts optimistic on news, but momentum-based.
Short-Term Outlook
Technicals show momentum with volume. RSI neutral aids upside. Momentum may push to resistance. Expect volatility; pullback possible on low float.
Medium to Long-Term Outlook
Business model scales with subscriptions. Medtech data market grows. Financials improved via debt cuts. Risks include execution on AI. Long-term investors should watch for revenue ramps before accumulating.
FAQ
Is ONMD stock a buy right now? Depends on risk tolerance. Growth potential exists, but volatility high.
What is the price target for ONMD stock? Average forecast $11.43; range $11-12. Limited coverage.
What are major risks for ONMD stock? Low revenue, competition, execution on AI.
ONMD earnings outlook? Bookings up 4.1x; focus on subscriptions.
ONMD forecast long-term? Bullish if data platform scales.
Suggestions
- Compare with Opendoor
- See our Microsoft stock forecast
- Read tech data sector valuation
Final Balanced Conclusion
Hold or watchlist ONMD stock. Growth drivers like AI excite, but tiny revenue and volatility caution. Suits risk-tolerant investors tracking catalysts.
Disclaimer: This article is for informational purposes only and not financial advice.